Clinical Cancer Drugs
Title:Meet Our Editor-in-Chief
Volume: 5
Author(s): Giulio Francia
Affiliation:
Export Options
About this article
Cite this article as:
Francia Giulio , Meet Our Editor-in-Chief, Clinical Cancer Drugs 2018; 5 (2) . https://dx.doi.org/10.2174/2212697X0502190131161027
DOI https://dx.doi.org/10.2174/2212697X0502190131161027 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |
31
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Current Bioactive Compounds Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Complex Obesity
Current Pediatric Reviews Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis
MicroRNA Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects
Current Pharmaceutical Biotechnology